These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35802524)

  • 1. Clinical Outcomes of Sotrovimab Treatment in 10 High-Risk Patients with Mild COVID-19: A Case Series.
    Takeda K; Kasai H; Sakao S; Saito M; Shikano K; Naito A; Abe M; Kawasaki T; Yahaba M; Taniguchi T; Igari H; Suzuki T
    Am J Case Rep; 2022 Jul; 23():e936832. PubMed ID: 35802524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
    JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2.
    Behzad A; Mohamed A; Ali A; Niinuma S; Butler AE; Alqahtani M
    J Infect Public Health; 2024 Feb; 17(2):315-320. PubMed ID: 38160562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.
    Chesdachai S; Rivera CG; Cole KC; Teaford HR; Gonzalez Suarez ML; Larsen JJ; Ganesh R; Tulledge-Scheitel S; Razonable RR
    Sci Rep; 2024 Mar; 14(1):5430. PubMed ID: 38443438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
    Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
    Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge.
    Piccicacco N; Zeitler K; Ing A; Montero J; Faughn J; Silbert S; Kim K
    J Antimicrob Chemother; 2022 Sep; 77(10):2693-2700. PubMed ID: 35913836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study.
    Woo MS; Brehm TT; Fischer M; Heyer A; Wichmann D; Jordan S; Nörz D; Lütgehetmann M; Addo MM; Lohse AW; Schmiedel S; Kluge S; Schulze Zur Wiesch J
    Microbiol Spectr; 2023 Feb; 11(1):e0410322. PubMed ID: 36475890
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO).
    Tuan JJ; Sharma M; Kayani J; Davis MW; McManus D; Topal JE; Ogbuagu O
    BMC Infect Dis; 2023 Apr; 23(1):258. PubMed ID: 37101135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records.
    Bell CF; Gibbons DC; Drysdale M; Birch HJ; Lloyd EJ; Patel V; Carpenter C; Carlson K; Calay ES; Puranik A; Wagner TE; O'Horo JC; Razonable RR
    PLoS One; 2024; 19(7):e0304822. PubMed ID: 39012863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series.
    Cicchitto G; Cardillo L; Sequino D; Sabatini P; Adamo L; Marchitiello R; Viscardi M; Cozzolino L; Cavallera A; Bocchino M; Sanduzzi Zamparelli A; Ferrigno F; de Carlo E; de Martinis C; Fusco G
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
    Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Falci DR; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Hebner CM; Sager J; Mogalian E; Tipple C; Peppercorn A; Alexander E; Pang PS; Free A; Brinson C; Aldinger M; Shapiro AE;
    N Engl J Med; 2021 Nov; 385(21):1941-1950. PubMed ID: 34706189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply to "successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients-A Czech multicenter experience": A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era.
    Cassin R; Rampi N; Anna Fidanza C; Muscatello A; Mariani B; Noto A; Rossi FG; Baldini L
    Hematol Oncol; 2023 Feb; 41(1):213-217. PubMed ID: 36156809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform.
    Zheng B; Green ACA; Tazare J; Curtis HJ; Fisher L; Nab L; Schultze A; Mahalingasivam V; Parker EPK; Hulme WJ; Bacon SCJ; DeVito NJ; Bates C; Evans D; Inglesby P; Drysdale H; Davy S; Cockburn J; Morton CE; Hickman G; Ward T; Smith RM; Parry J; Hester F; Harper S; Mehrkar A; Eggo RM; Walker AJ; Evans SJW; Douglas IJ; MacKenna B; Goldacre B; Tomlinson LA
    BMJ; 2022 Nov; 379():e071932. PubMed ID: 36384890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T
    Viruses; 2023 May; 15(6):. PubMed ID: 37376600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium.
    Drysdale M; Hautekiet T; Singh M; Hautekiet J; Ludikhuyze L; Patel V; Gibbons DC; De Roeck D; Colpaert K; Lloyd EJ; Van Braeckel E
    Acta Clin Belg; 2024 Jun; 79(3):174-183. PubMed ID: 39081095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era.
    Izumo T; Awano N; Kuse N; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Ota H; Inomata M
    Drug Discov Ther; 2022 Jul; 16(3):124-127. PubMed ID: 35753770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).
    Bell CF; Bobbili P; Desai R; Gibbons DC; Drysdale M; DerSarkissian M; Patel V; Birch HJ; Lloyd EJ; Zhang A; Duh MS;
    Clin Drug Investig; 2024 Mar; 44(3):183-198. PubMed ID: 38379107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19.
    Satram S; Ghafoori P; Reyes CM; Keeley TJH; Birch HJ; Brintziki D; Aldinger M; Alexander E; Lopuski A; Sarkis EH; Gupta A; Shapiro AE; Powers JH
    J Patient Rep Outcomes; 2023 Sep; 7(1):92. PubMed ID: 37702920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study.
    Lo CKL; Lo CKF; Komorowski AS; Leung V; Matic N; McKenna S; Perez-Patrigeon S; Sheth PM; Lowe CF; Chagla Z; Bai AD
    BMC Res Notes; 2024 Jan; 17(1):37. PubMed ID: 38267971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
    Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Molina KC; Peers JL; Russell S; Wynia MK; Ginde AA
    Int J Infect Dis; 2023 Mar; 128():310-317. PubMed ID: 36229005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.